Laminin 111 E8

Product Inquiry

Laminin 111 E8 Background

Laminin 111 is an extracellular matrix protein that has also been promoted for its ability to improve muscle regeneration and stabilize the plasma membrane in multiple forms of muscular dystrophy. Laminin 111 E8 is composed of the C-terminal end of Laminin alpha1, beta 1 and gamma 1 chains.

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
KN-057	KN-057; KN057	Phase 3 Clinical	Suzhou Alphamab Co Ltd	Hemophilia A; Hemophilia B	Details
MG-1113	MG-1113	Phase 1 Clinical	GC Biopharma Corp	Hemophilia A	Details
AP-017	AP017; AP-017	Phase 1 Clinical	Anyuan Pharmaceutical Technology (Shanghai) Co Ltd	Hemophilia A; Hemophilia B	Details

Marketed Drug Information

English Name	Research Code	Highest Development Stage	Company	Earliest Brand Name	Earliest Approval Country	Earliest Indication	Earliest Approval Company	Earliest Approval Date	Indication	Clinical Trial
Concizumab	mAbTFPI2021; NN-7415; NNC-0172-0000-2021; Anti-TFPI; mAb-2021; NNC-0172-2021; NNC-172-2021	Approved	Novo Nordisk A/S	Alhemo	Canada	Hemophilia B	Novo Nordisk Canada Inc	2023-04-17	Hemophilia A; Hemophilia B; Hemorrhage	Details
Marstacimab	PF-6741086; PF-06741086	Approved	Pfizer Inc	HYMPAVZI	United States	Hemophilia A; Hemophilia B	Pfizer Inc	2024-10-11	Hemophilia A; Hemophilia B; Hemorrhage	Details